Know Cancer

or
forgot password

I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma


N/A
N/A
N/A
Not Enrolling
Both
Neuroblastoma, Pheochromocytoma

Thank you

Trial Information

I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma


Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong
suspicion of neuroblastoma or pheochromocytoma.

Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of
I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after
administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid
uptake of free I-123-iodide


Inclusion Criteria:



- Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of
neuroblastoma or pheochromocytoma

Exclusion Criteria:

- Pregnancy

Type of Study:

Observational

Study Design:

Observational Model: Case-Only

Principal Investigator

Michael J Gelfand, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Children's Hospital Medical Center, Cincinnati

Authority:

United States: Food and Drug Administration

Study ID:

CCHMC# 88-12-2

NCT ID:

NCT00590096

Start Date:

January 1991

Completion Date:

December 2008

Related Keywords:

  • Neuroblastoma
  • Pheochromocytoma
  • Neuroblastoma
  • Pheochromocytoma
  • MIBG
  • Neuroblastoma
  • Pheochromocytoma

Name

Location